Vildagliptin
- Generic Name
- Vildagliptin
- Brand Names
- Galvus, Jalra, Xiliarx
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2
- CAS Number
- 274901-16-5
- Unique Ingredient Identifier
- I6B4B2U96P
- Background
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...
- Indication
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT00396071
- Locations
- 🇩🇪
Diabetes Zentrum Bad Lauterberg, Bad Lauterberg, Germany
🇨🇭Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 28
- Registration Number
- NCT00390520
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2008-11-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00389415
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1179
- Registration Number
- NCT00382096
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 21
- Registration Number
- NCT00380445
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇩🇪Novartis Investigative Site, Investigative Centers, Germany
A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.
- Conditions
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00380380
- Locations
- 🇩🇪
Munich, 81377, Germany, Munich, Germany
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2007-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 370
- Registration Number
- NCT00368134
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2007-05-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 236
- Registration Number
- NCT00351832
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 39
- Registration Number
- NCT00351585
A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT00351507
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.